Impact of Overdiagnosis on Long-Term Breast Cancer Survival

Jean Ching-Yuan Fann 1, King-Jen Chang 2, Chen-Yang Hsu 3, Amy Ming-Fang Yen 4, Cheng-Ping Yu 5,6, Sam Li-Sheng Chen 4, Wen-Hung Kuo 2, László Tabár 7 and Hsiu-Hsi Chen 3,8,*

1 Department of Health Industry Management, College of Healthcare Management, Kainan University, Taoyuan 338, Taiwan; jeanhann@ntu.edu.tw
2 Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan; kingjen@ntu.edu.tw (K.-J.C.); brcancer@gmail.com (W.-H.K.)
3 Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei 100, Taiwan; bacilli65@gmail.com
4 School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei 110, Taiwan; amyyen@tmu.edu.tw (A.M.-F.Y.); samchen@tmu.edu.tw (S.L.-S.C.)
5 Department of Pathology and Graduate Institute of Pathology and Parasitology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; cpyupath@yahoo.com.tw
6 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan
7 Department of Mammography, Falun Central Hospital, 791823 Falun, Sweden; laszlo@mammographyed.com
8 Innovation and Policy Center for Population Health and Sustainable Environment, College of Public Health, National Taiwan University, Taipei 100, Taiwan
* Correspondence: chenlin@ntu.edu.tw; Tel.: +886-2-3366-8033; Fax: +886-2-2358-7707

Received: 26 January 2019; Accepted: 4 March 2019; Published: 7 March 2019

Abstract: Elucidating whether and how long-term survival of breast cancer is mainly due to cure after early detection and effective treatment and therapy or overdiagnosis resulting from the widespread use of mammography provides a new insight into the role mammography plays in screening, surveillance, and treatment of breast cancer. Given information on detection modes, the impact of overdiagnosis due to mammography screening on long-term breast cancer survival was quantitatively assessed by applying a zero (cured or overdiagnosis)-inflated model design and analysis to a 15-year follow-up breast cancer cohort in Dalarna, Sweden. The probability for non-progressive breast cancer (the zero part) was 56.14% including the 44.34% complete cure after early detection and initial treatment and a small 11.80% overdiagnosis resulting from mammography screening program (8.94%) and high awareness (2.86%). The 15-year adjusted cumulative survival of breast cancer was dropped from 88.25% to 74.80% after correcting for the zero-inflated part of overdiagnosis. The present findings reveal that the majority of survivors among women diagnosed with breast cancer could be attributed to the cure resulting from mammography screening and accompanying effective treatment and therapy and only a small fraction of those were due to overdiagnosis.

Keywords: overdiagnosis; mammography screening; invasive breast cancer; zero-inflated Poisson regression model

1. Introduction

While the prognosis of breast cancer (BC) has been substantially improved due to early detection of breast cancer attributed to the widespread use of mammography, the issue of overdiagnosis resulting from mammography screening has been debated over the past decade [1–5]. As these overdiagnosed
cases are biologically indolent and non-progressive they would have never progressed to clinical phase and caused death due to breast cancer during the patients’ lifetime, implying that any treatment was unnecessary and would not have been administered had screening not been applied to these women [6–10].

The previous studies on the extent of overdiagnosis were estimated by excess incidence due to screening compared with background incidence derived from randomized control trials or predicted incidence extrapolated from previous unexposed epochs, making allowance for lead-time [2,9,11,12]. Note that these previous methods, while estimating the proportion of overdiagnosis, require individual normal and incident breast cancer data and also a strong assumption of lead-time distribution. These traditional approaches cannot be used for assessing the impact of overdiagnosis on long-term survival when only information on breast cancer cases and deaths from breast cancer is available.

Here, we propose a new approach to estimating overdiagnosis using information on the survival of breast cancer detected by different modalities (detection modes) together with prognostic factors with the premise that overdiagnosis of BC would not result in deaths from breast cancer. However, the survivors of these overdiagnosed BCs are often indistinguishable from those with of non-overdiagnosed BC cases but without potential of dying from breast cancer due to effective initial treatment and therapy, namely the completely cured. Both types are regarded as non-progressive BC with zero-probability of dying from BC but have manifestly different causes. To distinguish the completely cured patients from overdiagnosed ones requires information on detection mode such as screen-detected cases, interval cancers, and cancers in non-participants. The overestimation of cumulative survival due to the zero-probability of dying from breast cancer resulting from overdiagnosis would be expected if these overdiagnosed cases cannot be separated from the completely cured.

Moreover, the non-progressive BCs indicated above would also be mixed up with progressive BC patients still alive at each specific follow-up timepoint. Whether and when these progressive cases would die from BC is highly dependent on subsequent treatments and therapies and prognostic factors [13–18]. However, only relying on these prognostics may not be sufficient to distinguish between progressive and non-progressive BC because excellent survival tumors with good prognostic factors may also be a consequence of overdiagnosis due to mammography [19].

The aim of this study is therefore to apply the zero-inflated regression model to estimate the proportion of overdiagnosis resulting from mammography screening separated from the proportion of the completely cured due to effective treatment and therapy. We also assess the cumulative survival after correction for the zero-inflated part of overdiagnosis.

2. Materials and Methods

2.1. Study Subjects and Design

We quantified the respective contributions of overdiagnosis attributable to mammography and cures due to early detection and effective treatment by using a cohort composed of 1346 patients diagnosed with invasive BC at Falun Central Hospital of Dalarna County in Sweden in two periods with available information on prognostic factors, from 1996 to 1998 and from 2006 to 2010, in combination with a zero-inflated model design and analysis. The main reason of selecting two periods is mainly due to available information on immunohistochemical (IHC) markers, particularly HER2, which had not been widely tested before 2005. The period of 1996–1998 was a pilot phase for collecting such information. The two cohorts were followed over time until the end of 2010. Note that breast cancer service screening program with mammography has been offered since 1985 at the close of the Swedish Two-county randomized controlled trial [20].

In addition to longitudinal follow-up data, the current study design illustrated in Figure 1 is based on the concept of the zero-inflated model for solving the problem of being unable to distinguish between overdiagnosed cases from cured cases due to effective treatment and therapies as mentioned in
the introduction. All diagnosed breast cancers are classified into three types according to the potential for progression and the cure after initial treatment. The top left circle represents overdiagnosed cases (blue) with zero probability of dying from breast cancer mainly resulting from mammography screening. The dotted box is composed of those breast cancers with potential of progression, which are further divided into two types, the cured after initial treatment (green) and the cured after subsequent therapies during 15-year follow-up (red). The final column is the estimated attributable proportions among three types of survivors of breast cancer. If there is a lack of information on detection mode it is very difficult to distinguish the cured from the overdiagnosed. The screened cohort together with the collection of these prognostic factors provide an opportunity to distinguish overdiagnosis from the cured. The derivation of percentages among breast cancer cases delineated in Figure 1 is elaborated in the Statistical Analysis section and Appendix.

![Figure 1](image_url)

**Figure 1.** Study design for estimating the proportion of breast cancer survivors attributed to overdiagnosis, the completely cured after initial treatment, and the curation after subsequent therapies during 15-year follow-up.

### 2.2. Detection Mode Related to Curation and Overdiagnosis

There are three detection modes, screen-detected cases, interval cancers, and cancers from non-participants or outside the age ranges of screening. Here we assume overdiagnosis of BC due to mammography screening can only result from screen-detected cases as they were detected through mammography. Interval cancers after the exposure to a previous screen with negative findings were detected either through possible self-referral of patients or due to the presence of symptoms and signs. Cancers from non-participants or outside screening were diagnosed due to the presence of symptom and signs. In this sense, interval cancers would enhance awareness of being diagnosed as BC compared to cancers from non-participants. This can be supported by the fact that interval cancers have higher survival than cancers from non-participants [21]. Suppose treatment and therapies were administered to three groups according to the indication for the choice of treatment modality based on significant prognostic factors. The difference of zero probability on death from BC between screen-detected cancers and interval cancers would provide information on excess zeros due to overdiagnosis resulting from mammography. The difference of zero probability between interval cancers and cancers from non-participant offers information on overdiagnosis due to increased awareness. Details of the calculation are given in the statistical section.
2.3. Prognostic Factors

We collected factors responsible for progressive BCs including conventional tumor attributes (size, lymph node involvement, and histological grade), three immunohistochemical markers (ER, PR, HER2), triple negative (defined by these three IHC markers), surgical treatment and adjuvant therapy. Conventional tumor attributes have been collected since the dawn of the service screening. Surgical treatment (breast-conserving surgery, mastectomy, or others), and adjuvant therapy (radiotherapy, chemotherapy, or hormone therapy) had been collected since 1996.

Data on tumor phenotypes related to IHC markers including ER, PR and HER2 status were collected retrospectively for the period of 1996 to 1998 by standard antibody staining in the largest invasive tumor component for each patient and was described in full in previous studies [22]. The antibodies (supplier, type, dilution) used for staining are delineated as follows: ER (clone SP1; Ventana Medical Systems, Tucson, AZ, USA; 1:200 dilution), PR (clone PgR 636; Dako, Glostrup, Denmark; 1:50 dilution), and HER2 (code A 0485; Dako; 1:250 dilution). The cut-off point for ER and PR positivity is nuclear staining >10% of tumor cells. The criteria of HER2 positivity was offered by manufacturer. Triple negative BC is defined as a breast tumor with all ER, PR, and HER2 being negative.

2.4. Statistical Analysis

Descriptive data are presented with frequency and percentage. For categorical data, the chi-square test was used to compare the difference between groups and the Fisher Exact test was used if any count was less than 5. We first applied the Poisson regression model assuming the number of BC deaths follows a Poisson distribution. We estimated follow-up women years from the date of diagnosis as BC to the date of death from BC, loss of follow-up, or the end of this study as the offset in Poisson regression model. The value of deviance divided by degree of freedom provides an indicator to assess the extent of over-dispersion and under-dispersion for the specified Poisson regression model. For the elucidation of overdiagnosis in BC, we applied the zero-inflated Poisson (ZIP) regression model [23], which is a mixture of a Poisson regression model (count part) and a logistic regression model (zero part) as derived in Appendix A. The former model (Poisson regression model, count part) was used to evaluate the prognostic factors for progressive BCs. The prognostic factors included three conventional tumor attributes and treatment and therapies (surgery, chemotherapy, radiotherapy, hormone therapy). The latter model (logistic regression model, zero part) was used to estimate the probability of zero part (including overdiagnosis cases or cure after initial treatment and therapies) for non-progressive BCs. We used the detection mode of cancers as covariates to distinguish two types in the zero part (Appendix A). We then used the regression coefficients of logistic regression part in the ZIP model to calculate the probability of zero among all BCs and respective probabilities of zero by detection mode as detailed in Appendix A. The probability of overdiagnosis due to mammography screening and enhanced awareness is calculated as follows:

\[ \text{The probability of overdiagnosis due to mammography screening} = \left( \frac{\text{The probability of zero for screen-detected} - \text{the probability of zero for interval cancer}}{\text{The probability of zero among all BCs}} \right) \times \text{The probability of zero among all BCs} \] (1)

\[ \text{The probability of overdiagnosis due to awareness} = \left( \frac{\text{the probability of zero for interval cancers} - \text{the probability of zero for cancers from non-participants}}{\text{the probability of zero among all BCs}} \right) \times \text{The probability of zero among all BCs} \] (2)

\[ \text{The probability of cure due to treatment} = \text{The probability of zero among all BCs} - ((1) + (2)) \] (3)

We further derive 15-year cumulative survival curves with and without correcting for overdiagnosis by using the hazard rate derived from the ZIP model and the corresponding figure from the conventional Poisson regression model without considering overdiagnosis as described in
Appendix A). Two-sided \( p \)-value less than 0.05 was treated as statistical significance. All analyses were conducted with SAS version 9.4 (SAS Institute, Cary, NC, USA).

2.5. Ethics Approval

This study was approved by the Joint Institutional Review Board of Taipei Medical University (TMU-JIRB, approval numbers N201607008).

3. Results

Table 1 shows the frequencies of age at diagnosis, first generation prognostic factors (tumor size, node status, histologic malignancy grade), IHC markers (ER, PR, HER2, triple negative), and treatment and therapies by BC death. The distribution of age at diagnosis was similar between women who died from BC and those who did not. The distributions of tumor size, status of node involvement, histological grade, ER, PR, triple negative, surgery, and hormonal therapy were significantly different (\( p \)-value < 0.05) according to BC death. Women who had tumor size larger than 20 mm, positive nodes, grade 3, ER\((-\)), PR\((-\)), and triple negative were more likely to die from BC.

Table 1. The distribution of age at diagnosis, conventional tumor attributes, IHC markers (ER, PR, HER2, Triple negative), mammographic appearance, and treatment by status of breast cancer death.

| Variable/Level       | Breast Cancer Death |  \( p \)-Value |
|----------------------|---------------------|--------------|
|                      | No (\( n = 1228 \)) | Yes (\( n = 118 \)) |          |
| Age at diagnosis     |                     |              | 0.345    |
| <50                  | 202                 | 16           | 92.7     | 7.3  |
| 50–69                | 596                 | 53           | 91.8     | 8.2  |
| 70+                  | 430                 | 49           | 89.8     | 10.2 |
| Size *, mm           |                     |              | <0.001   |
| 1–9                  | 233                 | 4            | 98.3     | 1.7  |
| 10–14                | 273                 | 11           | 96.1     | 3.9  |
| 15–19                | 260                 | 13           | 95.2     | 4.8  |
| 20–29                | 263                 | 38           | 87.4     | 12.6 |
| \( \geq 30 \)        | 155                 | 30           | 83.8     | 16.2 |
| Nodes *              |                     |              | <0.001   |
| Negative             | 805                 | 39           | 95.4     | 4.6  |
| Positive             | 390                 | 57           | 87.2     | 12.8 |
| Grade *              |                     |              | <0.001   |
| 1                    | 284                 | 8            | 97.3     | 2.7  |
| 2                    | 633                 | 43           | 93.6     | 6.4  |
| 3                    | 263                 | 45           | 85.4     | 14.6 |
| ER *                 |                     |              | <0.001   |
| Negative             | 174                 | 33           | 84.1     | 15.9 |
| Positive             | 990                 | 57           | 94.6     | 5.4  |
| PR *                 |                     |              | <0.001   |
| Negative             | 448                 | 65           | 87.3     | 12.7 |
| Positive             | 714                 | 25           | 96.6     | 3.4  |
| HER2 *               |                     |              | 0.8771   |
| Negative             | 1018                | 78           | 92.9     | 7.1  |
| Positive             | 149                 | 12           | 92.5     | 7.5  |
| Triple negative *    |                     |              | <0.0001  |
| Yes                  | 115                 | 26           | 81.6     | 18.4 |
| No                   | 1046                | 64           | 94.2     | 5.8  |
Table 1. Cont.

| Variable/Level | Breast Cancer Death | p-Value |
|----------------|---------------------|---------|
|                | No (n = 1228) | % | Yes (n = 118) | % |
| Surgery *      | <0.0001           |       |               |   |
| MA             | 452                | 87.8  | 63            | 12.2 |
| BCS            | 538                | 95.9  | 23            | 4.1  |
| Others         | 238                | 88.1  | 32            | 11.9 |
| Chemotherapy   | 0.2018             |       |               |   |
| Yes            | 270                | 89.4  | 32            | 10.6 |
| No             | 958                | 91.8  | 86            | 8.2  |
| Radiotherapy   | 0.8979             |       |               |   |
| Yes            | 632                | 91.3  | 60            | 8.7  |
| No             | 596                | 91.1  | 58            | 8.9  |
| Tamoxifen      | 0.0061             |       |               |   |
| Yes            | 480                | 93.9  | 31            | 6.1  |
| No             | 748                | 89.6  | 87            | 10.4 |

Abbreviations: ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; IHC markers: immunohistochemical markers; PR: progesterone receptor; BCS: breast conserving surgery; MA: mastectomy.

* 66 subjects had no information on tumor size (44 survivors, 22 deaths), 55 subjects had no information on nodal involvement (33 survivors, 22 deaths), 70 subjects had no information on histological grade (48 survivors, 22 deaths), 92 subjects had no information on ER status (64 survivors, 28 deaths), 94 subjects had no information on PR status (66 survivors, 28 deaths), 89 subjects had no information on HER2 status (61 survivors, 28 deaths), 95 subjects had no information on triple negative status (67 survivors, 28 deaths).

Table 2 shows that conventional tumor attributes were significant predictors in both univariate and multivariable models. The crude RR was significantly higher for tumor with size 20–29 mm (9.32; 95% CI, 3.33–26.13) and 30 mm+ (13.65; 95% CI, 4.81–38.74) compared with size 1–9 mm, tumor with node positive (3.70; 95% CI, 2.46–5.57) compared with node negative, tumor with grade 3 (2.97; 95% CI, 1.99–4.43) compared with grade 1/2, and triple negative (3.32; 95% CI, 2.11–5.24) compared with non-triple negative cancers. In the multivariable analysis, tumor with size 20–29 mm (aRR = 2.63; 95% CI, 1.38–5.02) and 30+ mm (aRR = 2.39; 95% CI, 1.19–4.80) were at greater risk than those with size 1–9 mm. Positive node led to an elevated risk (aRR = 1.86; 95% CI, 1.18–2.94) as opposed to negative node after adjusting for variables related to treatment such as surgery, chemotherapy, radiotherapy, and hormonal therapy. Interpretation of effect size on treatment and therapies should be taken with great caution as they are not a reflection of efficacy of treatment and therapies but an indication for treatment and therapies according to tumor attributes. These accounted for the findings that those with mastectomy and radiotherapy had higher hazard of dying from breast cancer and insignificant effective chemotherapies and tamoxifen therapy even after adjustment for other significant prognostic factors.

The value of deviance divided by the degree of freedom, an indicator for assessing the level of over-dispersion, was about 0.46–0.59 in the univariate model and 0.49 in the multivariable model. As this value was less than 1, it strongly suggests the problem of under-dispersion (excess zeros).

We used data with complete information (n = 1233) on conventional tumor attributes, variables related to surgery and adjuvant therapy, and detection mode of BCs for the ZIP model analysis. The larger the value of odds ratio (OR), the higher probability to be cured after initial treatment or overdiagnosis. The larger the value of relative risk (RR), the higher the risk of dying from BC. Table 3 shows the estimated parameters, ORs, and RRs for the ZIP model.

Tumor size, node status, grade were significant factors related to risk of dying from BC after considering treatment. Compared with non-participants and outside screening of BCs, screen detected cancers and interval cancers were with higher odds (OR = 2.38, 95% CI: 0.97–5.85 and OR = 1.23, 95% CI: 0.48–3.17, respectively) of being zero.
Table 2. The univariate and multivariable analysis of Poisson regression model for predicting breast cancer death by conventional tumor attributes and other predictors.

| Variable/Level | Univariate | Multivariable |
|----------------|------------|---------------|
|                | cRR (95% CI) | p-Value | Deviance/df. | aRR (95% CI) | p-Value | Deviance/df. |
| Tumor size, mm |            |          |             |              |          |             |
| 10–14 vs. 1–9  | 2.53 (0.80–7.93) | <0.001 | 0.46  | 1.01 (0.45–2.24) | <0.001  | 0.49  |
| 15–19 vs. 1–9  | 3.12 (1.02–9.56) | 0.024 | 0.46  | 1.12 (0.52–2.43) | 0.025  | 0.49  |
| 20–29 vs. 1–9  | 9.32 (3.33–26.13) | 0.001 | 0.46  | 2.63 (1.38–5.02) | 0.001  | 0.49  |
| 30+ vs. 1–9    | 13.65 (4.81–38.74) | 0.001 | 0.46  | 2.39 (1.19–4.80) | 0.001  | 0.49  |
| Node (+) vs. (−) | 3.70 (2.46–5.57) | <0.001 | 0.46  | 1.86 (1.18–2.94) | 0.007  | 0.49  |
| Grade 3 vs. 1/2 | 2.97 (1.99–4.43) | <0.001 | 0.46  | 1.32 (0.84–2.07) | 0.228  | 0.49  |
| Triple negative Yes vs. No | 3.32 (2.11–5.24) | <0.001 | 0.46  | 1.53 (0.89–2.63) | 0.132  | 0.49  |
| Surgery MA vs. BCS | 4.02 (2.49–6.48) | <0.001 | 0.55  | 2.79 (1.56–4.98) | <0.001  | 0.55  |
| Chemotherapy Yes vs. no | 1.58 (1.05–2.37) | 0.027 | 0.59  | 0.83 (0.51–1.38) | 0.474  | 0.59  |
| Radiotherapy Yes vs. no | 0.71 (0.50–1.02) | 0.063 | 0.59  | 1.39 (0.82–2.37) | 0.215  | 0.59  |
| Tamoxifen Yes vs. no | 0.96 (0.64–1.45) | 0.849 | 0.59  | 0.89 (0.56–1.42) | 0.633  | 0.59  |

Abbreviations: aRR: adjusted relative risk; cRR: crude relative risk; df.: degree of freedom; MA: Mastectomy; BCS: Breast-conserving surgery.

The probability of zero part among all non-progressive BC was 56.14%. The corresponding probabilities for screen detected cancer, interval cancer, and refuser/outside screening cancers were 66.42%, 50.50%, and 45.40% respectively, which gave 8.94% overdiagnosis due to mammography screening and 2.86% due to high awareness for those interval cancers but exposed to mammography screening based on the equation (1) and (2). The probability of zero due to the curation resulting from early detection and effective treatment was 44.34% (Figure 1, green).

The 15-year prognosis-adjusted cumulative survival of BC after correcting for overdiagnosis fell from 88.25% (Figure 2, cross mark) to 74.80% (Figure 2, hollow circle) after further adjustment for prognostic factors in the count part of progressive BC (Figure 1, red). The 15-year survival rate among 43.86% progressive BC after subsequent treatments and adjuvant therapies was 32.11% after adjustment for significant prognostic factors (Figure 1, pink).

Table 3. The regression coefficient of Zero-inflated Poisson regression model and overdiagnosis rate.

| Variable                     | Regression Coefficient | S.E. | RR/OR (95% CI) | p-Value |
|------------------------------|------------------------|------|----------------|---------|
| Count Part                   | RR                     |      |                |         |
| Intercept                    | −6.216                 | 0.830| 3.69 (0.76–18.01) | 0.015   |
| Size, mm                     | 1.307                  | 0.808| 3.69 (0.76–18.01) | 0.015   |
| 10–14 vs. 1–9                | 1.348                  | 0.802| 3.69 (0.76–18.01) | 0.015   |
| 15–19 vs. 1–9                | 2.329                  | 0.769| 10.26 (2.27–46.33) | 0.015   |
| 20–29 vs. 1–9                | 2.246                  | 0.791| 9.45 (2.01–44.49) | 0.015   |
| Node (+) vs. (−)             | 0.877                  | 0.315| 2.40 (1.30–4.45)  | 0.005   |
| Grade 3 vs. 1/2              | 0.484                  | 0.276| 1.62 (0.94–2.79)  | 0.080   |
| Surgery MA vs. BCS           | 0.651                  | 0.360| 1.92 (0.95–3.88)  | 0.071   |
| Triple Negative No vs. Yes   | 0.914                  | 0.311| 2.49 (1.36–4.59)  | 0.003   |
| Chemotherapy Yes vs. No      | −0.238                 | 0.319| 0.79 (0.42–1.47)  | 0.456   |
| Radiotherapy Yes vs. No      | 0.210                  | 0.367| 1.23 (0.60–2.53)  | 0.568   |
| Tamoxifen Yes vs. No         | −0.054                 | 0.281| 0.95 (0.94–1.64)  | 0.847   |

Abbreviations: S.E.: Standard error; MA: Mastectomy; BCS: Breast-conserving surgery; SD: screen detected cancer; IC: interval cancer; RF: refuser & outside screening cancers.
with the zero-inflated design and model for separating the cured from the overdiagnosed provides a
solution but the conventional statistical model could not distinguish the completed cured after initial
treatment (green, Figure 1) and the curation after subsequent therapies during 15-year follow-up (red, Figure 1).
From the viewpoint of methodology, the use of the zero-inflated model enables us to separate the zero part with potential of progression but completely cured after initial treatment from the non-zero part with potential of progression but cured after subsequent therapies during 15-year
follow-up particularly when tumor attributes related to breast cancer progression were considered in the non-zero (progressive) part.

In addition to the assessment of the impact of overdiagnosis on long-term survival, our proposed zero-inflated model also provides an insight into the proportion of overdiagnosis resulting from mammography screening that has been well studied in previous studies using excess incidence approach with lead-time adjustment [2, 9, 11, 12]. After reviewing the primary articles that estimated the overdiagnosis level in European population-based mammography screening programs, Puliti et al. found that the rates of overdiagnosis of invasive BCs due to mammography screening varied from 0 to 54% [11]. Morrel et al. reported lower estimated baseline incidence resulted in higher level of overdiagnosis (42% vs. 30%) [24]. They also reported that longer lead-time (5 years vs. 2.5 years) contributed to lower extent of overdiagnosis (42% vs. 51%) [24]. Different background incidence rates and the assumption of lead-time distribution may account for such a wide range of estimates on overdiagnosis reported before. Several studies reported that the overdiagnosis rate was different by

4. Discussion

The long-term prognosis of BC has been substantially improved over the past three decades due to
early detection, mainly through mammographic screening. However, the harm of overdiagnosis is a
concomitant risk of the benefit of mammography screening and it has now become a debatable issue
and concern for population-based mammography screening over the past decade [1–5]. For breast
cancer cases with overdiagnosis, there is 0% probability of dying from BC and treatment is unnecessary
for them. It may also result in the overestimation of cumulative survival attributed to effective
treatment and therapies in accompany with early detection of mammography screening. The survival
of BC would thus be artificially inflated if such zero-inflated overdiagnosis is included. Estimating the
quantity of overdiagnosis separated from the cured due to treatment is intractable but indispensable
and can be truly a reflection of early detection and effective treatment and therapy. Our novel approach
with the zero-inflated design and model for separating the cured from the overdiagnosed provides

![Cumulative survival of breast cancer-based models with and without considering overdiagnosis.](image)

**Cumulative survival of breast cancer-based models with and without considering overdiagnosis.**
In addition to the disparity in the methodology of lead-time adjustment and the extent of mammography screening, variation of overdiagnosis across age may also be explained by the fact that background incidence rate and the distribution of lead-time also vary with age [2,9,11,12].

Our proposed alternative approach to evaluating the extent of overdiagnosis dispenses with background incidence of BC and the assumption of lead-time distribution. We only used empirical data on BCs with available information on detection mode, treatment and therapies, and prognostic factors collected from an organized service screening program after population-based randomized controlled trial on mammography screening since 1977 in Falun (also known as Dalarna now, and Kopparberg in the 1990s), Sweden [27]. This empirical data is well suited to estimate the overdiagnosis from mammography screening and enhanced awareness as the attendance rate of mammography screening was over 80% and women in this county were also with high awareness of being diagnosed as BC through interval cancers [4,6]. Information on BCs with various detection modes is therefore useful for separating the completed cured from overdiagnosis.

It is very interesting to note that the probability of being zero part among interval cancers was higher than refuser/outside screening BCs. The difference might result from high awareness of detecting BCs through interval cancers because they had been exposed to mammography screening. Our result showed about 3% overdiagnosis due to enhanced awareness of detecting BC through interval cancers.

There are two limitations of the current study. Although the application of ZIP enables us to estimate the attributable proportions of three types of breast cancer survivors, personalized prediction for three types cannot be achieved without more updated information on molecular and imaging biomarkers can be included in the zero part and non-zero part, respectively. The second is related to the validation of this zero-inflated model by the application of the proposed model together with the estimated parameters to independent prospective follow-up data of this cohort in the future and also to data outside this country. We therefore strongly suggest here that our proposed zero-inflated model had better be applied to other countries in Europe where mammography screening programs have been widely served since the 1990s and the screening rate was also high in order to see whether and how the cure, overdiagnosis, and the survival of progressive BCs vary with different service screening programs. We also suggest that our model can be applied to regions with lower mammography screening rates and lower awareness of detecting BC in contrast to the current data with high careening rate and enhanced awareness in order to test the generalizability of our proposed zero-inflated regression.

5. Conclusions

In conclusion, the zero-inflated model design is a novel approach to correcting cumulative survival of early-detected BC inflated due to the zero part of overdiagnosis. Application of this model to the Dalarna breast cancer service screening program revealed that, among all breast cancers detected from this program, there were 76% survivors (44% completely cured and 32% still alive) due to early detection of mammography and effective treatment after 15 years of follow-up and overdiagnosis accounted for 12% of survivors.

Author Contributions: Study concept and design: H.-H.C.; Acquisition and interpretation of data: W.-H.K., C.-P.Y., K.-J.C., L.T.; Literature search: K.-J.C., W.-H.K., C.-P.Y., J.C.-Y.F.; Drafting of the manuscript: J.C.-Y.F., C.-Y.H., K.-J.C., H.-H.C.; Critical revision of the manuscript for important intellectual content: L.T., K.-J.C., H.-H.C.; Statistical analysis: C.-Y.H., J.C.-Y.F., S.L.-S.C., A.M.-F.Y.; Obtained funding: S.L.-S.C., A.M.-F.Y., H.-H.C.; Administrative, technical, or material support: A.M.-F.Y., S.L.-S.C.

Funding: Ministry of Science and Technology Grant; Ministry of Education Grant. H.H.C., A.M.F.Y., S.L.S.C., and C.Y.H. are supported by the Ministry of Science and Technology grant (grant number MOST 106-2118-M-002-006-MY2; MOST 106-2118-M-038-002-MY2; MOST 106-2811-M-002-075; MOST 107-3017-F-002-003). H.H.C. is supported by The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Acknowledgments: This work was financially supported by the “Innovation and Policy Center for Population Health and Sustainable Environment (Population Health Research Center, PHRC), College of Public Health, National Taiwan University” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A Zero-Inflated Poisson Regression Model

Let $Y$ denote the random variable representing the observed counts of breast cancer death. The effect of demographic factors, tumor attributes, IHC (immunohistochemical markers), type of treatments and therapies for progressive BCs can be evaluated by using Poisson regression model specified as follows. The number of breast cancer death ($Y$) following Poisson distribution, the probability of having observation on $Y = y$ (say 118 death cases in Table 1) is written as follows:

$$
Pr(Y = y; \mu) = \frac{e^{-\mu} \mu^y}{y!}, \quad y = 0, 1, 2, \ldots, \mu > 0. \quad (A-1)
$$

The Poisson model can be extended to the zero-inflated Poisson (ZIP) model to account for the zero part (non-progressive BC), including the completely cured and over-diagnosis as diagrammed in Figure 1. By introducing the mixture probability, say $\pi$, of being non-progressive (zero-part) extended from (1), the ZIP is specified by:

$$
Pr(Y = y; \mu, \pi) = \begin{cases} 
\pi + (1-\pi)e^{-\mu} & \text{when } y = 0 \\
(1-\pi)\frac{e^{-\mu} \mu^y}{y!} & \text{when } y = 1, 2, 3\ldots 
\end{cases} \quad (A-2)
$$

$\mu > 0, 0 \leq \pi \leq 1$

The probability of having the observation on breast cancer death ($y = 1, 2, \ldots$) for progressive BCs is thus $(1-\pi)e^{-\mu}$, subject to the premise that the women must belong to the progressive breast cancer type with the probability specified by $(1-\pi)$. For women who would not die from breast cancer ($y = 0$), there are two possibilities, the zero part (complete cure and over-diagnosis) and progressive ones but who haven’t died at the specified follow-up time. The former is specified by the probability $\pi$ and the latter is thus the product of the complement scenario and survival probability written as $(1-\pi)e^{-\mu}$. Based on such a specification of the ZIP model, the effect of detection mode denoted by two dummy variables, SD and IC as follows:

$$
\logit(\pi) = \log\left(\frac{\pi}{1-\pi}\right) = \gamma_0 + \gamma_1SD + \gamma_2IC \quad (A-3)
$$

For a screen-detected subject, the vector of covariate is specified as $(SD = 1, IC = 0)$ and the vector of $(SD = 0, IC = 1)$ is thus for an interval cancer case. Due to our use of refuser as the reference group, the covariate vector of $(SD = 0, IC = 0)$ is specified for such type of case. The probability for being zero (non-progressive BC) is thus:

$$
\pi_i = \frac{\exp(\gamma_0 + \gamma_1SD_i + \gamma_2IC_i)}{1 + \exp(\gamma_0 + \gamma_1SD_i + \gamma_2IC_i)} \quad (A-4)
$$

The probability of being zero among all BCs without considering the covariate of detection mode was estimated as 56.14% using only the intercept term. Following the same rationale, the probability of being zero (non-progressive breast cancer) with the incorporation of detection mode was estimated as 66.42% for screen-detected, 50.50% for interval cancer, and 45.40% for cancers form non-participants or outside screening. According to the Equation (1) and (2) in the text of statistical section, 8.94% and 2.86% were estimated for over-diagnosis resulting from mammography and enhanced awareness, respectively.
In order to compare two cumulative survival curves as shown in Figure 2, we need to derive two annual death rates by using the ZIP model ($\lambda$) and the conventional Poisson model ($\lambda'$). For the ZIP model, number of breast cancer death is originated from the non-zero part with the following regression form:

$$\log(\mu) = \log(PY) + \beta_0 + \beta_1 x_1 + \beta_2 x_2 \ldots + \beta_p x_p$$  \hspace{1cm} (A-5)

The average counts of breast cancer death, say $\mu$, which can be further decomposed into the product of death rate ($\lambda$) and the person-year of the breast cancer cases under follow up ($PY$), is written as $\mu = \lambda \times PY$. By using log link, the association between average number of breast cancer death and breast cancer death rates and observed person-years is decomposed into $\log(\mu) = \log(\lambda) + \log(PY)$.

Breast cancer cases with certain characteristics such as large tumor size, higher grade of malignancy, positive lymph node involvement, triple negative cancer, etc., may have unfavorable prognosis and a higher rate of progression to breast cancer death. We denote these characteristics including demographic factors, tumor attributes, IHC markers, type of treatments and detection modes of a breast cancer case by vector $X (X = (X_1, X_2, X_3, \ldots, X_p))$. The effect of these $P$ characteristics on breast cancer case fatality rate can be incorporated by using log function written as follows:

$$\log(\lambda) = \beta_0 + \beta_1 x_1 + \beta_2 x_2 \ldots + \beta_p x_p,$$  \hspace{1cm} (A-6)

Based on the adjusted death rate derived from equation (A-6), the prognosis-adjusted survival with the ZIP model is derived by using $S(t) = \exp\{-\lambda t\}$ where $t$ is the follow-up time (in years) and $S(t)$ is the survival function for cumulative survival making allowance for overdiagnosis.

A similar logic can be applied to deriving prognosis-adjusted annual death rates ($\lambda'$) using the conventional Poisson regression model without considering the zero-inflated part in the light of $S'(t) = \exp\{-\lambda' t\}$ where $t$ is the follow-up time (in years) and $S'(t)$ is the survival function. The comparison of prognosis-adjusted 15-year cumulative survival between the model with and without adjusting for over-diagnosis was made and plotted in the Figure 2 of the main text.

References

1. Nelson, H.D.; Tyne, K.; Naik, A.; Bougatsos, C.; Chan, B.K.; Humphrey, L. Screening for breast cancer: An update for the US Preventive Services Task Force. *Ann. Intern. Med.* 2009, 151, 727–737. [CrossRef] [PubMed]

2. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: An independent review. *Lancet* 2012, 380, 1778–1786. [CrossRef]

3. Myers, E.R.; Moorman, P.; Gierisch, J.M.; Havrilesky, L.J.; Grimm, L.J.; Ghate, S.; Davidson, B.; Montgomery, C.R.; Crowley, M.J.; McCrory, D.; et al. Benefits and Harms of Breast Cancer Screening: A Systematic Review. *JAMA* 2015, 314, 1615–1634. [CrossRef] [PubMed]

4. Chen, H.H.; Yen, A.M.F.; Fann, J.C.Y.; Gordon, P.; Chiu, S.Y.H.; Hsu, C.Y.; Chang, K.J.; Lee, W.C.; Yeoh, K.G.; et al. Clarifying the debate on population-based screening for breast cancer with mammography: A systematic review of randomized controlled trials on mammography with Bayesian meta-analysis and causal model. *Medicine* 2017, 96, e5684. [CrossRef] [PubMed]

5. Brawley, O.W. Accepting the existence of breast cancer Overdiagnosis. *Ann. Intern. Med.* 2017, 166, 364–365. [CrossRef] [PubMed]

6. Duffy, S.W.; Aghaje, O.; Tabár, L.; Vitak, B.; Bjurstam, N.; Björneld, L.; Myles, J.P.; Warwick, J. Estimates of overdiagnosis from two trials of mammographic screening for breast cancer. *Breast Cancer Res. 2005, 7*, 258–265. [CrossRef] [PubMed]

7. Moss, S. Overdiagnosis in randomized controlled trials of breast cancer screening. *Breast Cancer Res.* 2005, 7, 230–234. [CrossRef] [PubMed]

8. Zackrisson, S.; Ancersson, I.; Janzon, L.; Manjer, J.; Garne, J.P. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: Follow-up study. *BMJ* 2006, 332, 689–692. [CrossRef] [PubMed]
9. Biesheuvel, C.; Barratt, A.; Howard, K.; Houssami, N.; Irwig, L. Effects of study methods and biases on estimates of invasive breast cancer over-detection with mammography screening: A systematic review. *Lancet Oncol.* 2007, 8, 1129–1138. [CrossRef]

10. EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. *J. Med. Screen* 2012, 19 (suppl. 1), 5–13. [CrossRef] [PubMed]

11. Pulitini, D.; Duffy, S.W.; Miccinesi, G.; De Koning, H.; Lynge, E.; Zappa, M.; Paci, E. Overdiagnosis in mammographic screening for breast cancer in Europe: A literature review. *J. Med. Screen* 2012, 19 (suppl. 1), 42–56. [CrossRef] [PubMed]

12. Coldman, A.; Phillips, N. Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. *CMAJ* 2013, 185, E498. [CrossRef] [PubMed]

13. Tabár, L.; Fagerberg, G.; Chen, H.H.; Duffy, S.W.; Gad, A. Tumour development, histology and grade of breast cancers: Prognosis and progression. *Int. J. Cancer* 1996, 66, 413–419. [CrossRef]

14. Chen, H.H.; Duffy, S.W.; Tabár, L. A mover-stayer mixture of Markov chain models for the assessment of dedifferentiation and tumour progression in breast cancer. *J. Appl. Stat.* 1997, 24, 265–278. [CrossRef]

15. Tabár, L.; Chen, H.H.; Duffy, S.W.; Krusemo, U.B. Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening. *Jpn. J. Clin. Oncol.* 1999, 29, 608–616. [CrossRef] [PubMed]

16. Fitzgibbons, P.L.; Page, D.L.; Weaver, D.; Thor, A.D.; Allred, D.C.; Clark, G.M.; Ruby, S.G.; O’Malley, F.; Simpson, J.F.; Connolly, J.L.; et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. *Arch. Pathol. Lab. Med.* 2000, 24, 966–978.

17. Parise, C.A.; Caggiano, V. Breast cancer survival defined by ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. *J. Cancer Epidemiol.* 2014, 2014, 469251. [CrossRef] [PubMed]

18. Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. *Clin. Cancer Res.* 2007, 13, 4429–4434. [CrossRef] [PubMed]

19. Norad, S.A.; Valenti, A.; Nofech-Mozed, S.; Sun, P.; Hanna, W. Tumour characteristics among women with very low-risk breast cancer. *Breast Cancer Res. Treat.* 2012, 134, 1241–1246.

20. Swedish Organised Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancer in Sweden. *Cancer* 2007, 109, 2205–2212. [CrossRef] [PubMed]

21. Biesheuvel, C.; Czene, K.; Orgeas, C.C.; Hall, P. The role of mammography screening attendance and detection mode in predicting breast cancer survival—is there added prognostic value? *Cancer Epidemiol.* 2011, 35, 545–550. [CrossRef] [PubMed]

22. Tot, T. Auxiliary lymph node status in unifocal, multifocal, and diffuse breast carcinomas: Differences are related to macrometastatic disease. *Ann. Surg. Oncol.* 2012, 19, 3395–3401. [CrossRef] [PubMed]

23. Bohning, D. Zero-inflated Poisson models and C. A. MAN.: A tutorial collection of evidence. *Biom. J.* 1988, 40, 833–843. [CrossRef]

24. Morrel, S.; Barratt, A.; Irwig, L.; Howard, K.; Biesheuvel, C.; Armstrong, B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. *Cancer Causes Control.* 2012, 21, 275–282. [CrossRef] [PubMed]

25. Zahl, P.H.; Strand, B.H.; Maehlen, J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: Prospective cohort study. *BMJ* 2004, 328, 921–924. [CrossRef] [PubMed]

26. Jonsson, H.; Johansson, R.; Lenner, P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. *Int. J. Cancer* 2005, 117, 842–847. [CrossRef] [PubMed]

27. Tabár, L.; Gad, A.; Ljungquist, U.; Holmberg, L.H.; Kopparberg County Project Group; Fagerberg, C.J.G.; Baldetorp, L.; Gröntoft, O.; Lundström, B.; Månson, J.C.; et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. *Lancet* 1985, 1, 829–832.

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).